scholarly journals Behind closed doors II: systematic analysis of prostate cancer patients' primary treatment consultations with radiation oncologists and predictors of satisfaction with communication

2011 ◽  
Vol 21 (8) ◽  
pp. 809-817 ◽  
Author(s):  
Thomas F. Hack ◽  
J. Dean Ruether ◽  
Tom Pickles ◽  
Barry D. Bultz ◽  
Dan Chateau ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Primary Treatment ◽  
Systematic Analysis ◽  
Radiation Oncologists

scholarly journals Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage

2017 ◽  
Vol 40 (9) ◽  
pp. 484-489 ◽  
Author(s):  
Katarina L. Matthes ◽  
Manuela Limam ◽  
Silvia Dehler ◽  
Dimitri Korol ◽  
Sabine Rohrmann
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Relative Survival ◽  
Primary Treatment ◽  
Treatment Choice ◽  
Over Time

scholarly journals National survey of radiation oncologists’ practice patterns regarding hormone-naïve prostate cancer with bone metastases

2020 ◽  
Vol 50 (10) ◽  
pp. 1188-1194
Author(s):  
Katsumasa Nakamura ◽  
Hitoshi Ishikawa ◽  
Tetsuo Akimoto ◽  
Manabu Aoki ◽  
Shinji Kariya ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Practice Patterns ◽  
Primary Treatment ◽  
Dose Fractionation ◽  
Radiation Oncologists ◽  
Multiple Bone Metastases ◽  
Single Bone ◽  
Radiotherapy Dose

Abstract Objective To explore radiation oncologists’ attitudes and practice patterns of radiotherapy for hormone-naïve prostate cancer with bone metastases in Japan. Methods An internet-based survey was distributed to board-certified radiation oncologists of the Japanese Society of Radiation Oncology. Three hypothetical cases were assumed: hormone-naïve prostate cancer with single, three or multiple non-symptomatic bone metastases. The respondents described their attitude regarding such cases, treatment methods and the radiotherapy dose fractionation that they would recommend. Results Among the 1013 board-certified radiation oncologists in Japan, 373 (36.8%) responded to the questionnaire. Most of the respondents (85.0%) believed that radiotherapy may be applicable as a primary treatment for hormone-naïve prostate cancer with bone metastases in some circumstances. For Case 1 (single bone metastasis), 55.0% of the respondents recommended radiotherapy for the prostate and bone metastasis. For Case 2 (three bone metastases), only 24.4% recommended radiotherapy for all lesions, and 31.4% recommended radiotherapy for the prostate only. For Case 3 (multiple bone metastases), 49.1% of the respondents stated that there was no indication for radiotherapy. However, 34% of the respondents still preferred to administer radiotherapy for the prostate. The radiotherapy techniques and dose fractionations varied widely among the respondents. Conclusion Most of the respondent radiation oncologists believed that radiotherapy may be beneficial for hormone-naïve prostate cancer with bone metastases.

scholarly journals Prostate cancer patients’ quality of life assessments across the primary treatment trajectory: ‘True’ change or response shift?

2016 ◽  
Vol 55 (7) ◽  
pp. 814-820 ◽  
Author(s):  
Christian Gerlich ◽  
Michael Schuler ◽  
Matthias Jelitte ◽  
Silke Neuderth ◽  
Michael Flentje ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Response Shift ◽  
Primary Treatment

Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial

2006 ◽  
Vol 24 (25) ◽  
pp. 4184-4189 ◽  
Author(s):  
Suzie J. Otto ◽  
Fritz H. Schröder ◽  
Harry J. de Koning
Keyword(s):  
Prostate Cancer ◽  
General Population ◽  
Cancer Patients ◽  
Cardiovascular Mortality ◽  
Randomized Study ◽  
Primary Treatment ◽  
Treatment Modalities ◽  
Prostate Cancer Treatment ◽  
Standardized Mortality Ratios

Purpose To estimate the risk of cardiovascular disease (CVD) mortality in prostate cancer patients in the Rotterdam section of European Randomized Study of Screening for Prostate Cancer, in both arms, and to compare this with the risk in the general population. Methods Standardized mortality ratios (SMRs) of cardiovascular mortality for 2,211 prostate cancer patients were calculated including analyses for treatment subgroups (surgery, radiotherapy, watchful waiting, and hormone therapy). Cardiovascular mortality was defined as death as a result of all CVD and as a result of coronary heart disease, acute myocardial infarction, other diseases of the heart, and cerebrovascular accidents. The prevalence of self-reported comorbidities at entry of the trial was evaluated as well. Results After a mean follow-up of 5.5 years, 258 prostate cancer patients (12%) had died. The SMR of all-cause mortality was 0.90 (95% CI, 0.79 to 1.01). The risk for cardiovascular mortality was low compared with that in the general population; the SMRs varied between 0.37 and 0.49. Low cardiovascular mortality risks were also seen within each treatment subgroup. CVD was the most frequently self-reported comorbidity at entry and prostate cancer patients undergoing radical prostatectomy reported the lowest rates (24%) compared with those receiving other therapies (40% to 42%). Conclusion Although some self-selection has occurred, prostate cancer treatment did not increase the risk of dying as a result of cardiovascular causes in our cohort. The risk was significantly lower for all primary treatment modalities, suggesting that less emphasis should be put on CVD as a contraindication for aggressive (surgical) treatment for prostate cancer patients.

Role of Metastasectomy in Prostate Cancer Patients Following Primary Treatment

2020 ◽  
pp. 211-221
Author(s):  
Gaëtan Devos ◽  
Antonino Battaglia ◽  
Lorenzo Tosco ◽  
Wouter Everaerts ◽  
Charlien Berghen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Primary Treatment
Sign in / Sign up

Export Citation Format

Share Document